Your search for tofacitinib returned 14 results

Methods to prevent and treat COVID-19 in cancer patients have had to evolve alongside the SARS-CoV-2 virus.

Results of the ORAL Surveillance study showed a higher risk for major adverse CV events and venous thromboembolism with tofacitinib vs TNFis.

The data were compared with the 2018 ACG and 2020 AGA guidelines for UC and the 2019 ACG and 2021 AGA guidelines for CD.

By identifying existing medications that may be repurposed for dementia, clinicians may be able to provide faster treatment for those in need.

Researchers compared the effectiveness of tofacitinib and vedolizumab among patients with UC who had experienced anti-TNF failure.

No reduction in ADRD risk seen for treatment with tofacitinib, tocilizumab, TNF inhibitors versus abatacept

Incidences of major adverse cardiovascular events, cancers higher with tofacitinib versus TNF inhibitor; criteria for noninferiority not met

JAK inhibitor baricitinib strongly recommended for the treatment of severe or critical COVID-19

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of December. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…

The approval was based on data from a phase 3 study which evaluated tofacitinib in adults with active AS who had an inadequate response to at least 2 NSAIDs.